Hereditary Cancer Panel denied due to quantity / dose limits by Carelon (formerly AIM)?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Carelon (formerly AIM) typically requires
NCCN-aligned for hereditary cancer testing. Pre-test genetic counseling required for many panels. Avalon overlap in some plans.
What works in the appeal
GC by ABGC-certified counselor (telegenetics qualifies). NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. Reroute to in-network lab if denial is contractual.
The Carelon (formerly AIM) angle on Hereditary Cancer Panel
## Why Carelon Denied Your Hereditary Cancer Panel Under Quantity Limits
Carelon (formerly AIM Specialty Health) applies frequency and quantity limits to genetic testing, and hereditary cancer panels are subject to "once per lifetime" or limited-repeat policies under most plans. A quantity-limit denial means the insurer's records show a prior hereditary cancer panel has already been covered, and the current request exceeds the permitted number of tests within the plan's coverage framework.
## Why This Denial Is Appealable
Quantity-limit policies for genetic testing are not clinically absolute. There are well-recognized clinical scenarios that justify repeat or additional panel testing: a prior test used an older, narrower gene set and did not include genes now considered clinically relevant for your indication; a prior test produced a variant of uncertain significance (VUS) and updated reclassification or confirmatory testing is needed; new personal or family history has emerged that changes your risk profile; or an updated guideline from a relevant professional organization now recommends a broader panel for your specific indication. Each of these is a documented, legitimate basis for a quantity-limit exception.
## Federal Appeal Framework
- Internal Appeal: ACA and ERISA §503 guarantee a full-and-fair internal appeal. File within the deadline on your denial letter.
- External Review: Under ACA §2719, after a final internal denial, you are entitled to independent external review by an accredited IRO, generally within four months. Expedited review is available for urgent clinical situations.
- ERISA Plans: Request the complete claims file, the prior test claim history, and the specific coverage policy governing repeat testing.
## Concrete Appeal Steps and Timeline
1. Identify the prior test in Carelon's records — confirm which test they consider the prior qualifying test. 2. Pull the prior test report — document the gene set, date, laboratory, and methodology. 3. Have your prescriber document the clinical distinction between the prior test and the current panel. 4. File internal appeal with the clinical rationale for why the quantity limit does not apply or why an exception is warranted. 5. File external review if internal appeal is denied.
## Documentation to Gather
- Complete prior test report showing exact genes analyzed, variants identified (or not), and testing methodology
- Prescriber letter explaining why the current panel is clinically distinct — specifically addressing: different gene coverage, updated variant classification needs, new family history, or guideline changes
- Updated family history documentation if new diagnoses have occurred in relatives
- VUS reclassification records or updated variant interpretation if applicable
- Current applicable guideline from the relevant professional organization (such as NCCN) supporting repeat or expanded testing for your indication — obtain directly from that organization
- Evidence that the repeat test will change clinical management
## Criteria-Mapping Structure
For each element of Carelon's quantity-limit exception criteria, document the chart fact:
| Exception Criterion | Your Supporting Evidence | |---|---| | Prior test used different/narrower gene set | Prior test report gene list vs. current panel gene list | | New clinical indication has emerged | Updated family history; new diagnosis records; VUS reclassification | | Results will change management | Prescriber statement on management implications | | Guideline supports expanded testing | Current guideline citation from applicable professional organization |
A side-by-side gene-set comparison between the prior test and the current panel — provided by your ordering provider or the laboratory — is often the single most persuasive document for overturning a quantity-limit denial.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →